Search

Terms & Conditions

EHA offers visitors a wide variety of information and a range of online services via its website.

About us

The European Hematology Association (EHA): “Towards prevention, cure, and quality of life for all patients with blood disorders”.

TimelinesApplication CBTH 2025
Deadline: September 24, 2024 (15:00 CEST)

Notification
November 2024

How to apply?Download the signature letter template. Fill in the template and get it duly signed for upload into the online application platform.

Thrombocytopenias and Platelet Function Disorders

The SWG was established at the 2003 EHA Congress, which was held in Lyon, France. The group's original focus was thrombocytopenias, but it subsequently expanded its field of interest with the inclusion of platelet function disorders.

Diagnosis in hematological diseases: morphology and flow cytometry

This SWG is active in disseminating knowledge on advances in the diagnosis and follow-up by morphology and multiparameter flow-cytometry of malignant and non-malignant hematological diseases. These include morphology, digital morphology, and flow-cytometry (mass, imaging, and spectral flow cytometry included).

Red Cells and Iron

This SWG covers the clinical areas of inherited and acquired disorders of the erythrocyte and iron metabolism.

European Research Initiative on CLL (ERIC)

ERIC is devoted to improving the outcome of patients with Chronic Lymphocytic Leukemia (CLL) and related diseases. The objectives of ERIC are to promote:

Research in all aspects of chronic lymphocytic leukemia and related diseases.

Infections in Hematology

The SWG on Infection in Hematology was founded in 2017 and follows four main goals:

Develop and share clinically useful tools: Many hematologists create checklists and pathways for quick and easy reference.

Quality of Life and Symptoms

The goals of the SWG are:

To promote the evaluation of patient-reported outcomes (PROs) in hematology in daily clinical practice and in clinical trials.

Chronic Myeloid Leukemia

The objective of this SWG is the cure of Chronic Myeloid Leukemia (CML) by cooperative research.